The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
Pravesh brings with him over 29 years of experience in leading complex manufacturing operations and driving operational excellence
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
